Raziel Therapeutics Ltd.   Report issue

For profit Phase 2
Founded: Jerusalem Israel (2012)

Organization Overview

First Clinical Trial
2017
NCT03171415
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Raziel Therapeutics | Raziel Therapeutics Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adiposis Dolorosa (Phase 2)

Lipedema (Phase 2)

Lipoma (Phase 2)

Obesity (Phase 2)

Overweight (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 5